id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2096-0009,FDA,FDA-2022-E-2096,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-27T05:00:00Z,2025,1,2025-01-27T05:00:00Z,,2025-01-27T17:10:59Z,,0,0,090000648690071a
FDA-2022-E-2096-0007,FDA,FDA-2022-E-2096,Decision on Petition to Transfer Patent Term Extension Proceeding From Original Patent to Reissue Patent,Other,Decision,2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:47:51Z,,0,0,0900006486613594
FDA-2022-E-2096-0006,FDA,FDA-2022-E-2096,"Petition to Transfer Patent Term Extension Application and Related Documents 
from U.S. Patent No. 9,969,689 to U.S. Patent No. RE49,948",Other,Petition(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:47:46Z,,0,0,0900006486613597
FDA-2022-E-2096-0008,FDA,FDA-2022-E-2096,Revised Decision on Petition to Transfer Patent Term Extension Proceeding From Original Patent to Reissue Patent,Other,Revision(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T20:47:58Z,,0,0,09000064866134fe
FDA-2022-E-2096-0005,FDA,FDA-2022-E-2096,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2024-02-05T05:00:00Z,2024,2,2024-02-05T05:00:00Z,,2024-02-05T19:17:01Z,,0,0,09000064863e5a39
FDA-2022-E-2096-0004,FDA,FDA-2022-E-2096,Determination of Regulatory Review Period for Purposes of Patent Extension; WELIREG,Notice,Determinations,2023-12-11T05:00:00Z,2023,12,2023-12-11T05:00:00Z,2024-02-10T04:59:59Z,2023-12-11T14:15:12Z,2023-27044,0,0,0900006486320e8b
FDA-2022-E-2096-0003,FDA,FDA-2022-E-2096,Letter to U S Patent and Trademark Office from FDA CDER,Other,Correspondence,2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T15:34:13Z,,0,0,09000064852f7ee0
FDA-2022-E-2096-0001,FDA,FDA-2022-E-2096,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:22:57Z,,0,0,090000648529dea5
FDA-2022-E-2096-0002,FDA,FDA-2022-E-2096,"Patent Extension Application from Merck Sharp & Dohme Corp. (on behalf of Peloton Therapeutics, Inc.)",Other,Application,2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:23:17Z,,0,0,090000648529dea8